BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

Jeffrey Alan Sosman, Adil Daud, Jeffrey S. Weber, Kevin Kim, Richard Kefford, Keith Flaherty, Jeffrey R. Infante, Omid Hamid, Jonathan S. Cebon, Lynn Mara Schuchter, Robert R. McWilliams, Mario Sznol, William Howard Sharfman, Alain Patrick Algazi, Karl D. Lewis, Shonda M. Little, Peng Sun, Georgina Long, Kiran Patel, Rene Gonzalez

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)9005-9005
Number of pages1
JournalJournal of Clinical Oncology
Issue number15 supplement
Publication statusPublished - 20 May 2013
EventAnnual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States
Duration: 31 May 20134 Jun 2013

Cite this